Results 271 to 280 of about 284,370 (314)
Some of the next articles are maybe not open access.
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer
British Journal of Cancer, 2023This study aimed to elucidate the clinicopathological and molecular features of HER2-amplified and HER2-low colorectal cancers (CRCs). We also characterised HER2 expression statuses in CRCs focusing on their intratumoral heterogeneity and alterations in metastatic lesions to establish practical HER2 status assessment.We evaluated 1009 CRCs for HER2 ...
Taiki Hashimoto +12 more
openaire +2 more sources
HER2 or Not HER2: That Is the Question
Journal of Clinical Oncology, 2005It is becoming increasingly apparent that the longappreciated clinical heterogeneity in breast cancer arises in large part from intrinsic biologic heterogeneity within the tumor. In other words, there is more than one type of breast cancer. Different tumor types are not merely arbitrarily defined subsets, but rather different diseases.
Harold J. Burstein, Eric P. Winer
openaire +1 more source
Seminars in Oncology, 2001
HER2 is a transmembrane growth factor receptor found in normal and malignant breast epithelial cells. Phosphorylation of the intracellular tyrosine kinase results in intracellular signaling and activation of genes involved in cell growth. Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response
Lohrisch, Caroline +1 more
openaire +3 more sources
HER2 is a transmembrane growth factor receptor found in normal and malignant breast epithelial cells. Phosphorylation of the intracellular tyrosine kinase results in intracellular signaling and activation of genes involved in cell growth. Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response
Lohrisch, Caroline +1 more
openaire +3 more sources
Truncated HER2: implications for HER2-targeted therapeutics
Drug Discovery Today, 2011The HER2 receptor is currently one of the flagship therapeutic targets in clinical oncology. Trastuzumab, an antibody targeting HER2, has become a foundation of care in women with HER2-positive breast cancer. However, many women with metastatic breast cancer do not respond to trastuzumab-based therapy.
Radoslaw, Zagozdzon +2 more
openaire +3 more sources
Loss of HER2 after HER2-targeted treatment
Breast Cancer Research and Treatment, 2019HER2 expression has been reported to be discordant between primary tumor and metastatic tissue.HER2 discordance and relation to HER2-targeted treatment was investigated in 227 patients with primary breast cancer.HER2 discordance between primary biopsy and second biopsy after neoadjuvant or adjuvant treatment was observed in 20.7%.
Tanja Ignatov +4 more
openaire +2 more sources
Clinical Breast Cancer, 2010
Last week in clinic, I was trying to explain HER2 and its effect on prognosis to a patient with newly diagnosed breast cancer. “It’s HER2 positive,” she said, “That’s bad, right?” Well, no, I explained, it used to be awful, but now it’s much better, and it’s going to get better yet in the not-too-distant future.
openaire +2 more sources
Last week in clinic, I was trying to explain HER2 and its effect on prognosis to a patient with newly diagnosed breast cancer. “It’s HER2 positive,” she said, “That’s bad, right?” Well, no, I explained, it used to be awful, but now it’s much better, and it’s going to get better yet in the not-too-distant future.
openaire +2 more sources
Seminars in Oncology, 2006
Variable expression of the HER2 receptor has been implicated in the pathogenesis of a number of malignancies. Many therapeutic modalities have been devised that target the receptor and downstream molecular pathways. The humanized monoclonal antibodies trastuzumab and pertuzumab bind epitopes on the extracellular domain, resulting in cell growth ...
Sumanta Kumar, Pal, Mark, Pegram
openaire +2 more sources
Variable expression of the HER2 receptor has been implicated in the pathogenesis of a number of malignancies. Many therapeutic modalities have been devised that target the receptor and downstream molecular pathways. The humanized monoclonal antibodies trastuzumab and pertuzumab bind epitopes on the extracellular domain, resulting in cell growth ...
Sumanta Kumar, Pal, Mark, Pegram
openaire +2 more sources
Cancer Research, 2023
Abstract Background: The HER2 antibody drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd) significantly improves outcomes over standard chemotherapy in pts with HER2-LOW (IHC 1+ and IHC 2+ FISH-) metastatic breast cancer (MBC).
Emanuel F. Petricoin +6 more
openaire +1 more source
Abstract Background: The HER2 antibody drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd) significantly improves outcomes over standard chemotherapy in pts with HER2-LOW (IHC 1+ and IHC 2+ FISH-) metastatic breast cancer (MBC).
Emanuel F. Petricoin +6 more
openaire +1 more source
Expert Review of Anticancer Therapy, 2013
In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clinical entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations.
Lorenza, Landi, Federico, Cappuzzo
openaire +2 more sources
In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clinical entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations.
Lorenza, Landi, Federico, Cappuzzo
openaire +2 more sources